> PerkinElmer has announced a deal to sell its aerospace unit and is in talks to auction off other units as it focuses on its life sciences operations. Article
> The UK's Reckitt Benckiser has agreed to pay $3.43 billion for Boots Group's nonprescription drug business. Boots had put the unit up for sale after announcing that it would merge with the drug distributor Alliance Unichem. Report
> Cytogen reports that a majority of bone cancer patients--eight out of 14--responded to a combination therapy of Quadramet combined with Eli Lilly's Gemzar. Report
> La Jolla Pharmaceutical plans to raise $66 million through a private placement. Report
> Vasogen Ireland has signed a deal to close a private placement for $40 million in senior notes. Release
> Teva Pharmaceutical has received tentative FDA approval for a generic version of Bristol-Myers Squibb's quinolone antibiotic Tequin Tablets. Release
> Researchers plan an independent study to see if they can replicate Repligen's mid-stage results for its schizophrenia drug RG1068. Report
And Finally… Researchers at the University of Illinois at Chicago believe that an hereditary brain protein deficiency may be linked to alcoholism. Article